ALK and non-Hodgkin lymphoma: Ensartinib in treating patients with relapsed or refractory advanced solid tumors, non-hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations (a pediatric MATCH treatment trial)